Eris Lifesciences Limited has successfully completed its strategic acquisition of Swiss Parenterals Limited, transforming the subsidiary into a wholly-owned entity through a preferential share allotment completed on January 16, 2026. The pharmaceutical company's Executive Committee approved the allotment of equity shares in exchange for the remaining 30% stake in Swiss Parenterals.

Share Allotment Details

The Executive Committee of Eris Lifesciences' Board approved the allotment of significant equity shares to complete the acquisition:

The allotment was made on a preferential basis through private placement to Mr. Naishadh Shah in exchange for his 16,74,493 equity shares of Swiss Parenterals Limited, representing the remaining 30% stake in the subsidiary.

Capital Structure Impact

The share allotment has resulted in changes to Eris Lifesciences' capital structure:

Regulatory Compliance and Approvals

The transaction was executed following comprehensive regulatory compliance. The company received in-principle approval from both NSE and BSE on January 9, 2026, for the preferential issue. The process began with the board meeting held on November 24, 2025, followed by shareholder approval through postal ballot on December 24, 2025.

The allotment complies with provisions of the Companies Act, 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly allotted shares will rank pari-passu with existing equity shares, subject to lock-in restrictions under SEBI ICDR Regulations.

Strategic Implications

With the completion of this acquisition, Swiss Parenterals Limited has become a wholly-owned subsidiary of Eris Lifesciences. This strategic move provides the company with enhanced control over Swiss Parenterals' operations and potential operational synergies. The subscription shares will be listed on NSE and BSE upon receipt of relevant listing approvals and will be subject to lock-in provisions as specified under Chapter V of the SEBI ICDR Regulations.

Eris Lifesciences Limited has successfully concluded its postal ballot voting process, with all four proposed resolutions receiving shareholder approval through remote e-voting that ended on December 24, 2025.

Postal Ballot Process Overview

The remote e-voting period commenced at 09:00 a.m. IST on November 25, 2025, and remained open until 17:00 hours IST on December 24, 2025. The company had initially issued the Postal Ballot Notice on November 24, 2025, which was subsequently updated through corrigenda dated December 5, 2025, and December 17, 2025.

Resolution Results Summary

All four resolutions were passed with overwhelming support from shareholders. The voting results demonstrate strong confidence from both promoter and public shareholders across different categories.

Resolution 1: Re-appointment of Whole-Time Director

The special resolution for re-appointing Mr. Krishnakumar Vaidyanathan as Whole-Time Director received substantial approval:

Resolution 2: Re-appointment of Independent Director

The special resolution to re-appoint Ms. Kalpana Unadkat as Independent Director also secured approval:

Resolution 3: Preferential Share Issuance

The special resolution for approval of issuance up to 23,06,372 fully paid-up equity shares on preferential basis for consideration other than cash received near-unanimous support:

Resolution 4: Related Party Transactions

The ordinary resolution to approve material related party transactions with Mr. Naishadh Shah was passed with strong support:

Compliance and Documentation

The voting results have been prepared in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All relevant documents, including the e-voting results and scrutinizer's report, have been uploaded on the company's website and the website of MUFG Intime India Private Limited, the registrar and transfer agent.

The successful completion of this postal ballot process enables Eris Lifesciences to proceed with its planned corporate actions, including the key appointments and the preferential share issuance, supporting the company's strategic initiatives.